Successful structure-based design of recent p38 MAP kinase inhibitors

Current Topics in Medicinal Chemistry

Volumn 9, Issue 7, 2009, Pages 655-676

  Karcher, Solveigh C ^a   Laufer, Stefan A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Binding modes; DFG in; DFG out; p38 inhibitors; p38 MAP kinase; Potency; Selectivity

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 4 PHENYLAMINO PYRROLOTRIAZINE DERIVATIVE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ADENINE; AMG 548; AVE 9940; BENZOPHENONE DERIVATIVE; BMS 582949; DORAMAPIMOD; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PAMAPIMOD; PH 797804; PHTHALAZINE DERIVATIVE; PLACEBO; PS 516895; PS 540446; PYRIDINE DERIVATIVE; PYRROLOTRIAZINE DERIVATIVE; RIBOSE; RO 3201195; RO 4402257; SB 681323; SB 85635; SC 80036; SCIO 469; TAK 715; TRIAZINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 702;

ACUTE CORONARY SYNDROME; ARTHRITIS; BINDING SITE; CHEMICAL STRUCTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CROHN DISEASE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG WITHDRAWAL; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IC 50; MULTIPLE MYELOMA; NEUROPATHIC PAIN; NONHUMAN; PROTEIN CONFORMATION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; TOOTH PAIN; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BINDING SITES; DRUG DESIGN; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350133698     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789007363     Document Type: Review

References (87)

1. Whitehouse, M. W. Drugs to treat inflammation: A historical introduction. Curr. Med. Chem. 2005, 12, 2931-2942.
2. Braddock, M.; Quinn, A. Targeting IL-1 in inflammatory disease: New opportunities for therapeutic intervention. Nat. Rev. Drug Discov. 2004, 3, 330-340.
3. Taylor, P. C. Anti-TNFalpha therapy for rheumatoid arthritis: An update. Intern. Med. 2003, 42, 15-20.
4. Palladino, M. A.; Bahjat, F. R.; Theodorakis, E. A.; Moldawer, L. L. Anti-TNF-alpha therapies: The next generation. Nat. Rev. Drug Discov. 2003, 2, 736-746.
5. Choy, E. H.; Panayi, G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 2001, 344, 907-916.
6. Schieven, G. L. The biology of p38 kinase: A central role in inflammation. Curr. Top. Med. Chem. 2005, 5, 921-928.
7. Schindler, J. F.; Monahan, J. B.; Smith, W. G. p38 pathway kinases as anti-inflammatory drug targets. J. Dent. Res. 2007, 86, 800-811.
8. Dinarello, C. A. Inflammatory cytokines: Interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr. Opin. Immunol. 1991, 3, 941-948.
9. Feldmann, M.; Brennan, F. M.; Maini, R. N. Rheumatoid arthritis. Cell 1996, 85, 307-310.
10. Rankin, E. C.; Choy, E. H.; Kassimos, D.; Kingsley, G. H.; Sopwith, A. M.; Isenberg, D. A.; Panayi, G. S. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 1995, 34, 334-342.
11. Present, D. H.; Rutgeerts, P.; Targan, S.; Hanauer, S. B.; Mayer, L.; Van Hogezand, R. A.; Podolsky, D. K.; Sands, B. E.; Braakman, T.; DeWoody, K. L.; Schaible, T. F.; Van Deventer, S. J. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 1999, 340, 1398-1405.
12. Jarvis, B.; Faulds, D. Etanercept: A review of its use in rheumatoid arthritis. Drugs 1999, 57, 945-966.
13. Mease, P. J.; Goffe, B. S.; Metz, J.; VanderStoep, A.; Finck, B.; Burge, D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356, 385-390.
14. Bresnihan, B. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. BioDrugs. 2001, 15, 87-97.
15. http://clinicaltrials.gov/ct/ [accessed April 15, 2009].
16. Dominguez, C.; Powers, D. A.; Tamayo, N. p38 MAP kinase inhibitors: Many are made, but few are chosen. Curr. Opin. Drug Discov. Devel. 2005, 8, 421-430.
17. Goldstein, D. M.; Gabriel, T. Pathway to the clinic: Inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr. Top. Med. Chem. 2005, 5, 1017-1029.
18. Dambach, D. M. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr. Top. Med. Chem. 2005, 5, 929-939.
19. Westra, J.; Limburg, P. C. p38 mitogen-activated protein kinase (MAPK) in rheumatoid arthritis. Mini Rev. Med. Chem. 2006, 6, 867-874.
20. Boldt, S.; Kolch, W. Targeting MAPK signalling: Prometheus' fire or Pandora's box? Curr. Pharm. Des. 2004, 10, 1885-1905.
21. Fabian, M. A.; Biggs, W. H.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329-336.
22. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26, 127-132
23. Lee, M. R.; Dominguez, C. MAP kinase p38 inhibitors: Clinical results and an intimate look at their interactions with p38alpha protein. Curr. Med. Chem. 2005, 12, 2979-2994.
24. Wrobleski, S. T.; Doweyko, A. M. Structural comparison of p38 inhibitor-protein complexes: A review of recent p38 inhibitors having unique binding interactions. Curr. Top. Med. Chem. 2005, 5, 1005-1016.
25. Wilson, K. P.; McCaffrey, P. G.; Hsiao, K.; Pazhanisamy, S.; Galullo, V.; Bemis, G. W.; Fitzgibbon, M. J.; Caron, P. R.; Murcko, M. A.; Su, M. S. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 1997, 4, 423-431.
26. Wang, Z. L.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; bdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Struct. Fold. Des. 1998, 6, 1117-1128.
27. Chen, M. H.; Fitzgerald, P.; Singh, S. B.; O'Neill, E. A.; Schwartz, C. D.; Thompson, C. M.; O'Keefe, S. J.; Zaller, D. M.; Doherty, J. B. Synthesis and biological activity of quinolinone and dihydroquinolinone p38 MAP kinase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 2222-2226.
28. Angell, R. M.; Bamborough, P.; Cleasby, A.; Cockerill, S. G.; Jones, K. L.; Mooney, C. J.; Somers, D. O.; Walker, A. L. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode. Bioorg. Med. Chem. Lett. 2008, 18, 318-323.
29. Herberich, B.; Cao, G. Q.; Chakrabarti, P. P.; Falsey, J. R.; Pettus, L.; Rzasa, R. M.; Reed, A. B.; Reichelt, A.; Sham, K.; Thaman, M.; Wurz, R. P.; Xu, S.; Zhang, D.; Hsieh, F.; Lee, M. R.; Syed, R.; Li, V.; Grosfeld, D.; Plant, M. H.; Henkle, B.; Sherman, L.; Middleton, S.; Wong, L. M.; Tasker, A. S. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold. J. Med. Chem. 2008, 51, 6271-6279.
30. http://www.ambitbio.com/technology/ [accessed April 20, 2009].
31. Traxler, P.; Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Therap. 1999, 82, 195-206.
32. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9, 268-272.
33. Okram, B.; Nagle, A.; Adrian, F. J.; Lee, C.; Ren, P.; Wang, X.; Sim, T.; Xie, Y.; Wang, X.; Xia, G.; Spraggon, G.; Warmuth, M.; Liu, Y.; Gray, N. S. A general strategy for creating "inactiveconformation" abl inhibitors. Chem. Biol. 2006, 13, 779-786.
34. Angell, R. M.; Angell, T. D.; Bamborough, P.; Bamford, M. J.; Chung, C. W.; Cockerill, S. G.; Flack, S. S.; Jones, K. L.; Laine, D. I.; Longstaff, T.; Ludbrook, S.; Pearson, R.; Smith, K. J.; Smee, P. A.; Somers, D. O.; Walker, A. L. Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg. Med. Chem. Lett. 2008, 18, 4433-4437.
35. Wrobleski, S. T.; Lin, S.; Hynes, J., Jr.; Wu, H.; Pitt, S.; Shen, D. R.; Zhang, R.; Gillooly, K. M.; Shuster, D. J.; McIntyre, K. W.; Doweyko, A. M.; Kish, K. F.; Tredup, J. A.; Duke, G. J.; Sack, J. S.; McKinnon, M.; Dodd, J.; Barrish, J. C.; Schieven, G. L.; Leftheris, K. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4] triazines as potent p38 alpha MAP kinase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 2739-2744.
36. Liao, J. J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem. 2007, 50, 409-424.
37. Peifer, C.; Wagner, G.; Laufer, S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem. 2006, 6, 113-149.
38. Wagner, G.; Laufer, S. Small molecular anti-cytokine agents. Med. Res. Rev. 2006, 26, 1-62.
39. Graneto, M. J.; Kurumbail, R. G.; Vazquez, M. L.; Shieh, H. S.; Pawlitz, J. L.; Williams, J. M.; Stallings, W. C.; Geng, L.; Naraian, A. S.; Koszyk, F. J.; Stealey, M. A.; Xu, X. D.; Weier, R. M.; Hanson, G. J.; Mourey, R. J.; Compton, R. P.; Mnich, S. J.; Anderson, G. D.; Monahan, J. B.; Devraj, R. Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase. J. Med. Chem. 2007, 50, 5712-5719.
40. Laufer, S. A.; Hauser, D. R.; Domeyer, D. M.; Kinkel, K.; Liedtke, A. J. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: Focus on optimized interactions with the enzyme's surface-exposed front region. J. Med. Chem. 2008, 51, 4122-4149.
41. Maier, J. A.; Brugel, T. A.; Clark, M. P.; Sabat, M.; Golebiowski, A.; Bookland, R. G.; Laufersweiler, M. J.; Laughlin, S. K.; VanRens, J. C.; De, B.; Hsieh, L. C.; Brown, K. K.; Juergens, K.; Walter, R. L.; Janusz, M. J. Development of N-2,4-pyrimidine-N-phenyl-N'-alkyl ureas as orally active inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 2. Bioorg. Med. Chem. Lett. 2006, 16, 3514-3518.
42. Kim, D. K.; Lim, J. H.; Lee, J. A.; Dewang, P. M. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase. Bioorg. Med. Chem. Lett. 2008, 18, 4006-4010.
43. Laufer, S.; Koch, P. Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity. Org. Biomol. Chem. 2008, 6, 437-439.
44. Scapin, G.; Patel, S. B.; Lisnock, J.; Becker, J. W.; LoGrasso, P. V. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem. Biol. 2003, 10, 705-712.
45. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
46. Laufer, S. A.; Zimmermann, W.; Ruff, K. J. Tetrasubstituted imidazole inhibitors of cytokine release: Probing substituents in the N-1 position. J. Med. Chem. 2004, 47, 6311-6325.
47. de, D. A.; Shih, C.; Lopez de, U. B.; Sanchez, C.; del, P. M.; Martin Cabrejas, L. M.; Pleite, S.; Blanco-Urgoiti, J.; Lorite, M. J.; Nevill, C. R., Jr.; Bonjouklian, R.; York, J.; Vieth, M.; Wang, Y.; Magnus, N.; Campbell, R. M.; Anderson, B. D.; McCann, D. J.; Giera, D. D.; Lee, P. A.; Schultz, R. M.; Li, L. C.; Johnson, L. M.; Wolos, J. A. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy. J. Med. Chem. 2005, 48, 2270-2273.
48. Dombroski, M. A.; Letavic, M. A.; McClure, K. F.; Barberia, J. T.; Carty, T. J.; Cortina, S. R.; Csiki, C.; Dipesa, A. J.; Elliott, N. C.; Gabel, C. A.; Jordan, C. K.; Labasi, J. M.; Martin, W. H.; Peese, K. M.; Stock, I. A.; Svensson, L.; Sweeney, F. J.; Yu, C. H. Benzimidazolone p38 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 919-923.
49. Mader, M.; de, D. A.; Shih, C.; Bonjouklian, R.; Li, T.; White, W.; Lopez de, U. B.; Sanchez-Martinez, C.; del, P. M.; Jaramillo, C.; de, D. E.; Martin Cabrejas, L. M.; Dominguez, C.; Montero, C.; Shepherd, T.; Dally, R.; Toth, J. E.; Chatterjee, A.; Pleite, S.; Blanco-Urgoiti, J.; Perez, L.; Barberis, M.; Lorite, M. J.; Jambrina, E.; Nevill, C. R., Jr.; Lee, P. A.; Schultz, R. C.; Wolos, J. A.; Li, L. C.; Campbell, R. M.; Anderson, B. D. Imidazolyl benzimidazoles and imidazo[4,5]-bpyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties. Bioorg. Med. Chem. Lett. 2008, 18, 179-183.
50. Young, P.; McDonnell, P.; Dunnington, D.; Hand, A.; Laydon, J.; Lee, J. Pyridinyl imidazoles inhibit IL-1 and TNF production at the protein level. Agents Actions 1993, 39 (Spec No), C67-C69.
51. Herlaar, E.; Brown, Z. p38 MAPK signalling cascades in inflammatory disease 10. Mol. Med. Today 1999, 5, 439-447.
52. Dumas, J.; Sibley, R.; Riedl, B.; Monahan, M. K.; Lee, W.; Lowinger, T. B.; Redman, A. M.; Johnson, J. S.; Kingery-Wood, J.; Scott, W. J.; Smith, R. A.; Bobko, M.; Schoenleber, R.; Ranges, G. E.; Housley, T. J.; Bhargava, A.; Wilhelm, S. M.; Shrikhande, A. Discovery of a new class of p38 kinase inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 2047-2050.
53. Salituro, F. G.; Germann, U. A.; Wilson, K. P.; Bemis, G. W.; Fox, T.; Su, M. S. Inhibitors of p38 MAP kinase: Therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem. 1999, 6, 807-823.
54. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J. Med. Chem. 2002, 45, 2994-3008.
55. Polmar, S. H.; Yong, C. L.; Wood, C. C.; Staehle, H.; Gupta, A. Safety and pharmacokinetics of an oral p38 MAP kinase inhibitor (BIRB 796 BS), administered twice daily for 14 days to healthy volunteers. J. Allergy Clin. Immunol. 2002, 109, S66.
56. Moss, N.; Breitfelder, S.; Betageri, R.; Cirillo, P. F.; Fadra, T.; Hickey, E. R.; Kirrane, T.; Kroe, R. R.; Madwed, J.; Nelson, R. M.; Pargellis, C. A.; Qian, K. C.; Regan, J.; Swinamer, A.; Torcellini, C. New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site. Bioorg. Med. Chem. Lett. 2007, 17, 4242-4247.
57. Goldberg, D. R.; Hao, M. H.; Qian, K. C.; Swinamer, A. D.; Gao, D. A.; Xiong, Z.; Sarko, C.; Berry, A.; Lord, J.; Magolda, R. L.; Fadra, T.; Kroe, R. R.; Kukulka, A.; Madwed, J. B.; Martin, L.; Pargellis, C.; Skow, D.; Song, J. J.; Tan, Z.; Torcellini, C. A.; Zimmitti, C. S.; Yee, N. K.; Moss, N. Discovery and optimization of p38 inhibitors via computer-assisted drug design. J. Med. Chem. 2007, 50, 4016-4026.
58. Cogan, D. A.; Aungst, R.; Breinlinger, E. C.; Fadra, T.; Goldberg, D. R.; Hao, M. H.; Kroe, R.; Moss, N.; Pargellis, C.; Qian, K. C.; Swinamer, A. D. Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. 2008, 18, 3251-3255.
59. Leftheris, K.; Ahmed, G.; Chan, R.; Dyckman, A. J.; Hussain, Z.; Ho, K.; Hynes, J., Jr.; Letourneau, J.; Li, W.; Lin, S.; Metzger, A.; Moriarty, K. J.; Riviello, C.; Shimshock, Y.; Wen, J.; Wityak, J.; Wrobleski, S. T.; Wu, H.; Wu, J.; Desai, M.; Gillooly, K. M.; Lin, T. H.; Loo, D.; McIntyre, K. W.; Pitt, S.; Shen, D. R.; Shuster, D. J.; Zhang, R.; Diller, D.; Doweyko, A.; Sack, J.; Baldwin, J.; Barrish, J.; Dodd, J.; Henderson, I.; Kanner, S.; Schieven, G. L.; Webb, M. The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase. J. Med. Chem. 2004, 47, 6283-6291.
60. Liu, C.; Wrobleski, S. T.; Lin, J.; Ahmed, G.; Metzger, A.; Wityak, J.; Gillooly, K. M.; Shuster, D. J.; McIntyre, K. W.; Pitt, S.; Shen, D. R.; Zhang, R. F.; Zhang, H.; Doweyko, A. M.; Diller, D.; Henderson, I.; Barrish, J. C.; Dodd, J. H.; Schieven, G. L.; Leftheris, K. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase. J. Med. Chem. 2005, 48, 6261-6270.
61. Das, J.; Moquin, R. V.; Pitt, S.; Zhang, R.; Shen, D. R.; McIntyre, K. W.; Gillooly, K.; Doweyko, A. M.; Sack, J. S.; Zhang, H.; Kiefer, S. E.; Kish, K.; McKinnon, M.; Barrish, J. C.; Dodd, J. H.; Schieven, G. L.; Leftheris, K. Pyrazolo-pyrimidines: A novel heterocyclic scaffold for potent and selective p38 alpha inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 2652-2657.
62. Hynes, J., Jr.; Dyckman, A. J.; Lin, S.; Wrobleski, S. T.; Wu, H.; Gillooly, K. M.; Kanner, S. B.; Lonial, H.; Loo, D.; McIntyre, K. W.; Pitt, S.; Shen, D. R.; Shuster, D. J.; Yang, X.; Zhang, R.; Behnia, K.; Zhang, H.; Marathe, P. H.; Doweyko, A. M.; Tokarski, J. S.; Sack, J. S.; Pokross, M.; Kiefer, S. E.; Newitt, J. A.; Barrish, J. C.; Dodd, J.; Schieven, G. L.; Leftheris, K. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors 3. J. Med. Chem. 2008, 51, 4-16.
63. Sack, J. S.; Kish, K. F.; Pokross, M.; Xie, D.; Duke, G. J.; Tredup, J. A.; Kiefer, S. E.; Newitt, J. A. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase. Acta Crystallogr. D Biol. Crystallogr. 2008, D64, 705-710.
64. Lin, J.; Wrobleski, S. T.; Liu, C.; Leftheris, K. Preparation of pyrrolopyrrolotriazines as p38 kinase inhibitors. US Pat. 2006019928. 2006.
65. Angell, R. M.; Angell, T. D.; Bamborough, P.; Brown, D.; Brown, M.; Buckton, J. B.; Cockerill, S. G.; Edwards, C. D.; Jones, K. L.; Longstaff, T.; Smee, P. A.; Smith, K. J.; Somers, D. O.; Walker, A. L.; Willson, M. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR. Bioorg. Med. Chem. Lett. 2008, 18, 324- 28.
66. Angell, R.; Aston, N. M.; Bamborough, P.; Buckton, J. B.; Cockerill, S.; deBoeck, S. J.; Edwards, C. D.; Holmes, D. S.; Jones, K. L.; Laine, D. I.; Patel, S.; Smee, P. A.; Smith, K. J.; Somers, D. O.; Walker, A. L. Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity. Bioorg. Med. Chem. Lett. 2008, 18, 4428-4432.
67. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46, 3-26.
68. Pettus, L. H.; Wurz, R. P. Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: Novel structures and developments during 2006-2008. Curr. Top. Med. Chem. 2008, 8, 1452-1467.
69. Pettus, L. H.; Xu, S.; Cao, G. Q.; Chakrabarti, P. P.; Rzasa, R. M.; Sham, K.; Wurz, R. P.; Zhang, D.; Middleton, S.; Henkle, B.; Plant, M. H.; Saris, C. J.; Sherman, L.; Wong, L. M.; Powers, D. A.; Tudor, Y.; Yu, V.; Lee, M. R.; Syed, R.; Hsieh, F.; Tasker, A. S. 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase. J. Med. Chem. 2008, 51, 6280- 292.
70. Boger, J. Vertex Press Release: Vertex Moves to Re-allocate Resources from VX-745 in p38 MAP Kinase Program to Accelerate Development of Second Generation Drug Candidates VX-702 and VX-850; Cambrige, Sept. 24, 2001 http://www.prnewswire.com/cgi-bin/ stories.pl?ACCT=104&STORY=/www/story/09-24-2001/ 0001577269&EDATE= [accessed May 03, 2009].
71. Natarajan, S. R.; Wisnoski, D. D.; Singh, S. B.; Stelmach, J. E.; O'Neill, E. A.; Schwartz, C. D.; Thompson, C. M.; Fitzgerald, C. E.; O'Keefe, S. J.; Kumar, S.; Hop, C. E. C. A.; Zaller, D. M.; Schmatz, D. M.; Doherty, J. B. p38 MAP kinase inhibitors. Part 1: Design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold. Bioorg. Med. Chem. Lett. 2003, 13, 273-276.
72. Stelmach, J. E.; Liu, L.; Patel, S. B.; Pivnichny, J. V.; Scapin, G.; Singh, S.; Hop, C. E.; Wang, Z.; Strauss, J. R.; Cameron, P. M.; Nichols, E. A.; O'Keefe, S. J.; O'Neill, E. A.; Schmatz, D. M.; Schwartz, C. D.; Thompson, C. M.; Zaller, D. M.; Doherty, J. B. Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. 2003, 13, 277-280.
73. Hunt, J. A.; Kallashi, F.; Ruzek, R. D.; Sinclair, P. J.; Ita, I.; McCormick, S. X.; Pivnichny, J. V.; Hop, C. E.; Kumar, S.; Wang, Z.; O'Keefe, S. J.; O'Neill, E. A.; Porter, G.; Thompson, J. E.; Woods, A.; Zaller, D. M.; Doherty, J. B. p38 Inhibitors: Piperidine-and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones. Bioorg. Med. Chem. Lett. 2003, 13, 467-470.
74. Liu, L.; Stelmach, J. E.; Natarajan, S. R.; Chen, M. H.; Singh, S. B.; Schwartz, C. D.; Fitzgerald, C. E.; O'Keefe, S. J.; Zaller, D. M.; Schmatz, D. M.; Doherty, J. B. SAR of 3,4-dihydropyrido[3,2-d]pyrimidone p38 inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 3979-3982.
75. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural basis for p38a MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struct. Mol. Biol. 2003, 10, 764-769.
76. Natarajan, S. R.; Doherty, J. B. P38 MAP kinase inhibitors: Evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes. Curr. Top. Med. Chem. 2005, 5, 987-1003.
77. Natarajan, S. R.; Heller, S. T.; Nam, K.; Singh, S. B.; Scapin, G.; Patel, S.; Thompson, J. E.; Fitzgerald, C. E.; O'Keefe, S. J. p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design. Bioorg. Med. Chem. Lett. 2006, 16, 5809-5813.
78. Hill, R. J.; Dabbagh, K.; Phippard, D.; Li, C.; Suttmann, R. T.; Welch, M.; Papp, E.; Song, K. W.; Chang, K. C.; Leaffer, D.; Kim, Y. N.; Roberts, R. T.; Zabka, T. S.; Aud, D.; Dal, P. J.; Manning, A. M.; Peng, S. L.; Goldstein, D. M.; Wong, B. R. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: Preclinical analysis of efficacy and selectivity. J. Pharmacol. Exp. Ther. 2008, 327, 610-619.
79. Cohen, S. B.; Cheng, T. T.; Chindalore, V.; Damjanov, N.; Burgos-Vargas, R.; Delora, P.; Zimany, K.; Travers, H.; Caulfield, J. P. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 2009, 60, 335-344.
80. Goldstein, D. M.; Alfredson, T.; Bertrand, J.; Browner, M. F.; Clifford, K.; Dalrymple, S. A.; Dunn, J.; Freire-Moar, J.; Harris, S.; Labadie, S. S.; La, F. J.; Lapierre, J. M.; Larrabee, S.; Li, F.; Papp, E.; McWeeney, D.; Ramesha, C.; Roberts, R.; Rotstein, D.; San, P. B.; Sjogren, E. B.; So, O. Y.; Talamas, F. X.; Tao, W.; Trejo, A.; Villasenor, A.; Welch, M.; Welch, T.; Weller, P.; Whiteley, P. E.; Young, K.; Zipfel, S. Discovery of S-[5-amino-1-(4-fluorophenyl)- 1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)ph enyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. J. Med. Chem. 2006, 49, 1562-1575.
81. Mavunkel, B. J.; Chakravarty, S.; Perumattam, J. J.; Luedtke, G. R.; Liang, X.; Lim, D.; Xu, Y. J.; Laney, M.; Liu, D. Y.; Schreiner, G. F.; Lewicki, J. A.; Dugar, S. Indole-based heterocyclic inhibitors of p38alpha MAP kinase: Designing a conformationally restricted analogue. Bioorg. Med. Chem. Lett. 2003, 13, 3087-3090.
82. Thalhamer, T.; McGrath, M. A.; Harnett, M. M. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008, 47, 409-414.
83. Navas, T. A.; Nguyen, A. N.; Hideshima, T.; Reddy, M.; Ma, J. Y.; Haghnazari, E.; Henson, M.; Stebbins, E. G.; Kerr, I.; O'Young, G.; Kapoun, A. M.; Chakravarty, S.; Mavunkel, B.; Perumattam, J.; Luedtke, G.; Dugar, S.; Medicherla, S.; Protter, A. A.; Schreiner, G. F.; Anderson, K. C.; Higgins, L. S. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006, 20, 1017-1027.
84. Murali Dhar, T. G.; Wrobleski, S. T.; Lin, S.; Furch, J. A.; Nirschl, D. S.; Fan, Y.; Todderud, G.; Pitt, S.; Doweyko, A. M.; Sack, J. S.; Mathur, A.; McKinnon, M.; Barrish, J. C.; Dodd, J. H.; Schieven, G. L.; Leftheris, K. Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds. Bioorg. Med. Chem. Lett. 2007, 17, 5019-5024.
85. Ottosen, E. R.; Sorensen, M. D.; Bjoerkling, F.; Skak-Nielsen, T.; Fjording, M. S.; Aaes, H.; Binderup, L. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J. Med. Chem. 2003, 46, 5651-5662.
86. Laufer, S. A.; Ahrens, G. M.; Karcher, S. C.; Hering, J. S.; Niess, R. Design, Synthesis, and Biological Evaluation of Phenylamino-Substituted 6,11-Dihydro-dibenzo[b,e]oxepin-11-ones and Dibenzo [a,d]cycloheptan-5-ones: Novel p38 MAP Kinase Inhibitors. J. Med. Chem. 2006, 49, 7912-7915.
87. Linsenmaier. Entwicklung und Optimierung von in Vitro Testverfahren zur Evaluierung von Hemmstoffen der p38 MAP Kinase und JNK3. Dissertation, University of Tuebingen, Germany, 2006.